On July 8, Align Technology fell 5.03% in regular trading, trading at approximately $175.66/share, with turnover of $33.52 million.

On the news front, the European Commission formally launched an antitrust investigation into Align Technology on June 30, focusing on whether the company abused its dominant market position by bundling its iTero intraoral scanners with Invisalign clear aligners and restricting competitors' scanner interoperability. The investigation noted that since 2017, Align Technology has refused to approve competing scanners for automatic order file submission. This marks the EU's first antitrust case in the medical device industry.

While Align Technology characterized the probe as a procedural step that does not predetermine the outcome, market concerns over potential penalties and forced business model adjustments have continued to weigh on shares. The company's next earnings report is scheduled for July 29, with expected EPS of $2.08.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)